Upstream Bio, Inc. is a clinical-stage biotechnology company headquartered in Waltham, Massachusetts, specializing in the development of innovative therapies for severe inflammatory diseases, particularly respiratory disorders. The company is committed to addressing significant unmet medical needs with a robust pipeline of therapeutic candidates designed to change the treatment landscape for patients suffering from complex inflammatory conditions. With a strong focus on research and development, Upstream Bio aims to make substantial contributions to the biotechnology sector while enhancing patient outcomes and advancing healthcare solutions. Show more
Location: 890 WINTER STREET, WALTHAM, MA, UNITED STATES, 02451, Waltham, MA, 02451, USA | Website: https://upstreambio.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE
Market Cap
1.261B
52 Wk Range
$5.14 - $33.68
Previous Close
$31.08
Open
$31.10
Volume
783,021
Day Range
$29.64 - $32.38
Enterprise Value
1.309B
Cash
72.16M
Avg Qtr Burn
-22.24M
Insider Ownership
14.94%
Institutional Own.
92.81%
Qtr Updated
09/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Verekitug Details Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 Data readout | |
Verekitug Details Severe asthma | Phase 2 Data readout | |
Verekitug Details Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) | Phase 2 Update |